Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London 30 October 2025
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets 28 October 2025
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting 22 October 2025
